Geriatric oncology in resource-limited settings

Immunotherapy developments and new agents for locally advanced NSCLC and SCLC

GIST tumours and soft tissue sarcomas

Challenges in interpreting comprehensive biomarker testing and a few paths to address them

Updates on triple-negative breast cancer and immunotherapy

Predictive and prognostic biomarkers for immunotherapy in lung cancer

Gynaecological cancer: New targets and immunotherapy developments

Molecular oncology and translational medicine

Immunotherapy in NSCLC: Adjuvant and neoadjuvant clinical scenarios

Adjuvant nivolumab vs placebo in resected oesophageal or gastroesophageal junction cancer following chemo: Biomarker analysis

Lenvatinib plus pembrolizumab versus standard of care for previously treated metastatic colorectal cancer

Whole exome sequencing reveals genomic landscape of appendiceal adenocarcinoma